ELI LILLY IN INDIA
Ans: - 1
1993 -Eli Lilly, a leading pharma company in US, started a JV in India with Ranbaxy looking at the local market knowledge. It was the only multinational company which was not present in India. US market conditions and rising opportunity in India were main reasons for the JV.
Strict governmental control prevailed in US and costs increased, Prices soared in 90s, Generic’s arrival in US market compared to low cost manufacturing in India and easing regulations that opened Indian market to FDI (51% CAP) created opportunities to enter Indian market for pharma companies of the world.
JV with Ranbaxy was a smart move by Eli Lilly to establish itself in India. Ranbaxy was the 2nd largest company of bulk drugs and generics …show more content…
Government approvals and In-licensing got easier.
4. Strong and cohesive working relationship.
5. Credibility as an international company of pharmaceuticals.
6. Increased business in exports and use of international distribution network. Ranbaxy became no 1 in 2000 in gross sales in Indian companies.
Ans: - 4
Global challenges and Trends of Pharma Industry by 2000-01:
1. Large Number of Acquisitions and Mergers would increase the competition in the market they have to be prepared.
2. Core prescriptions which generate high profits are focus areas.
3. Approval for new drugs are becoming difficult and lengthy.
4. Rising Costs of drugs manufacturing and pressures to contain.
5. Rising competition from Generics.
Recommendations for Eli-Lily:
1. Focused Marketing and promotion of Patent products in Indian market. Patents will expire in near future and Generic players will grab it.
2. Clear roadmap of resource utilization of Ranbaxy and growth expansion in Asia Pacific.
Recommendations for Ranbaxy:
1. More focus on Research and Development, use of Eli-Lily’s research expertise to develop won capabilities.
2. Global manufacturing facilities, benchmarked to international standards.
3. Aggressive International Expansion to wherever Eli-Lily’s presence
Ans: - 1
1993 -Eli Lilly, a leading pharma company in US, started a JV in India with Ranbaxy looking at the local market knowledge. It was the only multinational company which was not present in India. US market conditions and rising opportunity in India were main reasons for the JV.
Strict governmental control prevailed in US and costs increased, Prices soared in 90s, Generic’s arrival in US market compared to low cost manufacturing in India and easing regulations that opened Indian market to FDI (51% CAP) created opportunities to enter Indian market for pharma companies of the world.
JV with Ranbaxy was a smart move by Eli Lilly to establish itself in India. Ranbaxy was the 2nd largest company of bulk drugs and generics …show more content…
Government approvals and In-licensing got easier.
4. Strong and cohesive working relationship.
5. Credibility as an international company of pharmaceuticals.
6. Increased business in exports and use of international distribution network. Ranbaxy became no 1 in 2000 in gross sales in Indian companies.
Ans: - 4
Global challenges and Trends of Pharma Industry by 2000-01:
1. Large Number of Acquisitions and Mergers would increase the competition in the market they have to be prepared.
2. Core prescriptions which generate high profits are focus areas.
3. Approval for new drugs are becoming difficult and lengthy.
4. Rising Costs of drugs manufacturing and pressures to contain.
5. Rising competition from Generics.
Recommendations for Eli-Lily:
1. Focused Marketing and promotion of Patent products in Indian market. Patents will expire in near future and Generic players will grab it.
2. Clear roadmap of resource utilization of Ranbaxy and growth expansion in Asia Pacific.
Recommendations for Ranbaxy:
1. More focus on Research and Development, use of Eli-Lily’s research expertise to develop won capabilities.
2. Global manufacturing facilities, benchmarked to international standards.
3. Aggressive International Expansion to wherever Eli-Lily’s presence